Dare Bioscience Inc (DARE)

Jan 9, 2025, 8:00 AM EST - 8 days ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 14, 2024, 8:03 PM EST - 2 months ago

Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:01 PM EST - 2 months ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 7, 2024, 8:00 AM EST - 2 months ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Oct 23, 2024, 12:30 PM EDT - 3 months ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 21, 2024, 8:05 AM EDT - 3 months ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Aug 12, 2024, 8:40 PM EDT - 5 months ago

Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 4:01 PM EDT - 5 months ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Jul 19, 2024, 8:00 AM EDT - 6 months ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 1, 2024, 6:54 AM EDT - 7 months ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Jun 27, 2024, 8:00 AM EDT - 7 months ago

Daré Bioscience Announces Reverse Stock Split

May 14, 2024, 6:30 PM EDT - 8 months ago

Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:00 AM EDT - 8 months ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 2, 2024, 8:00 AM EDT - 9 months ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Apr 30, 2024, 7:30 AM EDT - 9 months ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 23, 2024, 8:00 AM EDT - 9 months ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 11, 2024, 8:00 AM EDT - 10 months ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Mar 28, 2024, 8:47 PM EDT - 10 months ago

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 8:00 AM EDT - 10 months ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 21, 2024, 8:00 AM EDT - 10 months ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 15, 2024, 2:33 PM EDT - 11 months ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN BTMD

Jan 31, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 26, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 17, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 4, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Dec 26, 2023, 8:00 AM EST - 1 year ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Dec 20, 2023, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Dec 13, 2023, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Nov 9, 2023, 9:56 PM EST - 1 year ago

Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 8:00 AM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 6, 2023, 8:00 AM EST - 1 year ago

Daré Bioscience to Participate in Three November Conferences

Nov 1, 2023, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 10, 2023, 8:00 AM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Aug 9, 2023, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings

Aug 3, 2023, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023

Jul 11, 2023, 5:30 PM EDT - 1 year ago

Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems

Jun 21, 2023, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women

Jun 14, 2023, 8:00 AM EDT - 1 year ago

Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference

Jun 9, 2023, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, the Journal of the International Menopause Society

May 11, 2023, 10:10 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q1 2023 Earnings Call Transcript

May 11, 2023, 8:00 AM EDT - 1 year ago

Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update

May 4, 2023, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023

Mar 30, 2023, 11:16 PM EDT - 1 year ago

Dare Bioscience, Inc. (DARE) Q4 2022 Earnings Call Transcript

Mar 30, 2023, 8:00 AM EDT - 1 year ago

Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update

Mar 23, 2023, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023

Mar 1, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience to Present at the 35th Annual Roth Conference

Feb 22, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1

Feb 1, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience to Participate in Three February Conferences

Nov 10, 2022, 8:45 PM EST - 2 years ago

Dare Bioscience, Inc. (DARE) Q3 2022 Earnings Call Transcript